Cannabinoid - Potential of Treating Diabetes | cannabisMD

Cannabinoid – Potential of Treating Type 1 and 2 Diabetes

Cannabinoids Treating Type 1 and Type 2 Diabetes

There have been numerous studies performed on animal subjects to test for potential health benefits in the case of using cannabis to tackle diabetes. Research that has been conducted has implied that the use of cannabis may help with stabilising blood sugars, preventing nerve inflammation, lowering blood pressure over time, keeping blood vessels opened and improving circulation.

After studies executed on mice, researchers provided evidence that the mice and their metabolism increased which in turn, lowered levels of cholesterol in the blood and/or fat within the liver.

This paper will look at how cannabinoids can offer salvation from those suffering at the hands of neuropathic pain in rat models of type 1 and type 2 diabetes.

Here is the full scientific article if you wish to download it.

Cannabinoids Have a Therapeutic Effect in Those Suffering With Diabetes


Diabetic neuropathy is a common complication of diabetes mellitus with a massive effect on patients’ quality of life, and it remains badly treated. Cannabinoids relieve the signs of diabetic neuropathy in different experimental models, including streptozotocin- (STZ-) induced type 1 diabetic rats, and they may also alleviate neuropathic signs in type 2 diabetic animals.

This study compares the impact of the nonspecific cannabinoid agonist WIN 55,212-2 (WIN) in Zucker Diabetic Fatty (ZDF) rats (type 2 diabetes) and in STZ-injected Wistar rats (type 1 diabetes). WIN (or its vehicle) was either systemically administered at a non-psychoactive dose or locally injected. Selective CB1 and CB2 cannabinoid antagonists were used to describe WIN antineuropathic impacts.

Cannabinoids May Be More Effective Than Existing Diabetes Medication

Both type 1 and type 2 diabetic rats showed mechanical allodynia but not thermal hyperalgesia. WIN alleviated mechanical allodynia in both models of diabetes. In STZ-treated rats, both cannabinoid receptors were included, whereas in ZDF rats, WIN impacts seemed to mainly involve the triggering of CB1 receptors. Greater doses of WIN were needed to massively alleviate mechanical allodynia upon intraplantar administration in ZDF vs. STZ-injected rats.

Cannabinoids, acting on systemic and/or peripheral receptors, may just as a new therapeutic alternative for symptom management in painful neuropathy associated with both type 1 and type 2 diabetes. Additionally, these conclusions highlight the need for appropriate selection of diabetic experimental models because the results from studies in STZ-induced diabetic rodents might not be useful in all diabetic situations.

Jonathan Neilly
Jonathan Neilly
Jonathan Neilly is registered with the British Psychological Society, breaking the taboo on mental health issues is one of the driving forces in his life. His background in biomedicine gives him additional understanding of the factors that work together to influence the human condition.

Leave a Reply

Your email address will not be published. Required fields are marked *